Reading the tape
NASDAQ: ACET
Adicet Bio, Inc.
Healthcare · Biotechnology
Market Cap
$81.67M
52w High
$17.44
52w Low
$6.01
P/E
-0.50
Volume
106.45K
Outstanding Shares
9.60M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -19.68%FCF (TTM): -3.73%
What changed
The stock fell 19.68% over the last year. Free cash flow declined 3.73% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
CEOChen Schor
SectorHealthcare
IndustryBiotechnology
Employees152
IPO dateJan 26, 2018
Valuation
Forward P/E—
EV/EBITDA-0.29
Enterprise value$33.85M
Stock splits
Dec 30, 2025↓ Reverse
Every 16 shares became 1
Sep 16, 2020↓ Reverse
Every 7 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-73.36%▼16.89%vs FY2024
Analyst consensus
RatingBuy
Target price$18.00▲111.52%
9
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$3.08 · Revenue est —
View